These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24832841)

  • 1. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres.
    Balogh O; Brodszky V; Gulácsi L; Herédi E; Herszényi K; Jókai H; Kárpáti S; Baji P; Remenyik É; Szegedi A; Holló P
    Eur J Health Econ; 2014 May; 15 Suppl 1():S101-9. PubMed ID: 24832841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.
    Herédi E; Rencz F; Balogh O; Gulácsi L; Herszényi K; Holló P; Jókai H; Kárpáti S; Péntek M; Remenyik É; Szegedi A; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1():S111-9. PubMed ID: 24832842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.
    Ghatnekar O; Ljungberg A; Wirestrand LE; Svensson A
    Eur J Dermatol; 2012; 22(2):238-45. PubMed ID: 22361745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of health-related quality of life in psoriasis patients in Hungary].
    Poór AK; Sárdy M; Cserni T; Brodszky V; Holló P; Gulácsi L; Remenyik É; Szegedi A; Rencz F; Péntek M
    Orv Hetil; 2018 May; 159(21):837-846. PubMed ID: 29779387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.
    Rencz F; Gulácsi L; Péntek M; Poór AK; Sárdy M; Holló P; Szegedi A; Remenyik É; Brodszky V
    Br J Dermatol; 2018 Nov; 179(5):1102-1108. PubMed ID: 29968311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Disease burden of psoriasis associated with psoriatic arthritis in Hungary].
    Rencz F; Brodszky V; Péntek M; Balogh O; Remenyik E; Szegedi A; Holló P; Kárpáti S; Jókai H; Herszényi K; Herédi E; Szántó S; Gulácsi L
    Orv Hetil; 2014 Nov; 155(48):1913-21. PubMed ID: 25417138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.
    Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions.
    Rencz F; Poór AK; Péntek M; Holló P; Kárpáti S; Gulácsi L; Szegedi A; Remenyik É; Hidvégi B; Herszényi K; Jókai H; Beretzky Z; Brodszky V
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):783-790. PubMed ID: 29114942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
    Tang MM; Chang CC; Chan LC; Heng A
    Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis.
    Maul JT; Fröhlich F; Maul LV; Stunnenberg R; Valenzuela F; De La Cruz C; Vera-Kellet C; Armijo D; Cesar WG; Carvalho A; Didaskalu JA; Graf N; Egeberg A; Wu JJ; Thyssen JP; Romiti R; Griffiths CEM
    Br J Dermatol; 2023 Mar; 188(4):533-541. PubMed ID: 36653920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health status and costs of ambulatory patients with multiple sclerosis in Hungary.
    Péntek M; Gulácsi L; Rózsa C; Simó M; Iljicsov A; Komoly S; Brodszky V
    Ideggyogy Sz; 2012 Sep; 65(9-10):316-24. PubMed ID: 23126217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
    Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
    Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
    Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
    Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil.
    Lopes N; Dias LLS; Azulay-Abulafia L; Oyafuso LKM; Suarez MV; Fabricio L; Kobata CM; Cestari T; Gontijo B; Sabbag CY; Antonio JR; Romiti R; Pertel PC
    Adv Ther; 2019 Oct; 36(10):2849-2865. PubMed ID: 31432463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.